Newsletter
2022 iPSC Manufacturing Summit in Boston, MA; July 26-28, 2022 | ASC
Join Applied StemCell’s President and CEO, Dr. Ruby Yanru Chen-Tsai on June 27 at the iPSC Manufacturing Summit in Boston, MA. Dr. Chen-Tsai will present ASC’s latest advancements in establishing a master iPSC line for safe large cargo insertion for the development of efficacious iPSC-CAR-iNK allogeneic products. We hope to see you there.
Seminar: Establish Master iPSC for Targeted Large-Cargo Integration and its Application in Developing Safe and Efficacious iPSC-CAR-iNK Allogeneic Product
Synopsis
- Allogeneic cell product
- Safe and efficient gene insertion TARGATTTM technology
- Application in iPSC-CAR-iNK cell therapy
Date: Wednesday, July 27 (Day One)
Time: 12:15 pm
Register: https://ipsc-manufacturing-summit.com/
About the Speaker:
Dr. Chen-Tsai received her PhD from Cornell University and did her post-doc research at Stanford University. She has been doing research in genome editing and stem cells for over 20 years. Prior to joining ASC, Dr. Chen-Tsai worked at Stanford University for 16 years as the Director of Transgenic Research Center and Associate Director of the Stanford Cancer Institute. Her most recent research at Stanford focused on using Parkinson patient-specific iPS cell lines, gene modification, and their differentiation to dopaminergic neurons as a disease model-in-a-dish. She is a co-inventor of the TARGATT™ integrase technology for site-specific gene insertion. Dr. Chen-Tsai is an author of many scientific papers and holder of over fifteen patents. Prior to becoming the CEO of Applied StemCell, Dr. Chen-Tsai led the ASC Therapeutics' gene/cell therapeutic product development for 5 years. She also led the successful filing of three pre-IND (one stem cell therapy, one gene therapy and one gene editing therapy) with the FDA.
About Applied StemCell, Inc.
Applied StemCell, Inc. (ASC) is a leading cell and gene therapy CRO/CDMO headquartered in California, USA. With over 13 years of iPSC and genome editing experience, Applied StemCell offers comprehensive research- and GMP-grade iPSC and gene editing solutions for the development of gene and cell products. We established a TARGATT™ master iPSC platform for safe and efficient, site-specific, and large cargo (up to 20kb) transgene integration (> 40% insertion efficiency without selection). This platform is currently used for the development of allogeneic iPSC-CAR-NK products. ASC is on a mission to assist in the development and manufacturing of novel therapeutics, and we seek to form partnerships focused on iPSC-based therapies.
Media Contact:
Maki Ogawa
Marketing Director, Applied StemCell, Inc.
408-773-8007
maki.ogawa@appliedstemcell.com